VEGFA and neoplasm: More than half of the patients underwent sorafenib treatment 9 weeks after TACE, and yet the production of VEGF by triggering ischemic conditions might just exist for a short time [32], which reminded us that the condition of high expression of PD-1 and the increasing tumor-specific CD8 + T cell response in the tumor microenvironment might disappear soon.